Clinical Research Directory

Inclusion Criteria: * Patients between the ages of 40-70 years. NB: Patients under the age of 40 who are considered unsuitable for a myeloablative transplant may enrol onto the trial following discussion with the CI via the Trials Office * Patients with ALL in first or second CR * Availability of a human leukocyte antigen (HLA) identical sibling or suitable matched donor (suitable matched defined as no greater than a single allele mismatch at HLA A, B, C or DRβ1). A single allele mismatch is permitted if there are adverse cytogenetics or MRD positivity at any timepoint * Patients considered suitable to undergo a RIC allogeneic SCT as clinically judged by the Local Investigator including:- * Adequate hepatic and renal function as determined by full blood count and biochemistry assessment * Resolution of any toxic effects of prior therapy (including radiotherapy, chemotherapy or surgical procedures). Patients with bone marrow suppression following therapy may enter the trial * Patients with abnormal cardiac and/or pulmonary function must be considered fit for allogeneic SCT including 8Gy of TBI at the time of randomisation. * Patients with an ECOG performance status 0,1 or 2 * Females of and male patients of reproductive potential (i.e., not post-menopausal or surgically sterilised) must use appropriate, highly effective, contraception from the point of admission for transplant conditioning therapy until 12 months after transplant (see section 8.1.2.2) * Patients have given written informed consent * Patients willing and able to comply with scheduled study visits and laboratory tests Exclusion Criteria: * Patients with contraindications to receiving RIC allogeneic SCT * Female patients who are pregnant or breastfeeding. All women of childbearing potential (WOCBP) must have a negative pregnancy test before commencing treatment * Adults of reproductive potential not willing to use appropriate, effective, contraception during the specified period * Patients with renal or hepatic impairment as clinically judged by Local Investigator * Patients with active infection, HIV-positive or chronic active Hep-A or -C * Patients with concurrent active malignancy. Patients with a previous history of malignancy can be included if that malignancy is considered to be at a low risk of recurrence * Previous exposure to a high dose of radiotherapy